Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca receives approval for skin infections treatment
The FDA approval is based on results from one of the largest studies conducted to date of hospitalized patients with complicated skin and skin structure infections (cSSSI). The
The FDA approval is based on results from one of the largest studies conducted to date of hospitalized patients with complicated skin and skin structure infections (cSSSI). The
The findings have been described as highly significant for systemic onset juvenile idiopathic arthritis (SoJIA) patients for whom previous therapies have failed. In a study of nine SoJIA
This is the second time in recent weeks that the FDA has denied approval of Risperdal (risperidone) for the treatment of a new disease. Earlier this month Johnson
Myogen has also achieved three development milestones under an existing research collaboration with Novartis, which has been in operation since 2003. Achievement of these milestones will trigger payments
The European Patent Organization granted the patent for the Mycobacterial Cell Wall-DNA Complex (MCC), which comprises compositions with antiviral, immune adjuvant, and immune stimulatory activity, as well as
AP23573 was recently designated as a fast-track product by the FDA for the treatment of sarcomas. Ariad hopes oral administration would permit greater flexibility in dosing and greater
The research suggests Virulizin activates the innate immune system of the host. Previous studies have shown that Virulizin induces the antitumor activity of macrophages, and that natural killer
This testing is intended to support a larger scale study planned for later this year as part of the US regulatory approval process. Scolr Pharma received authorization from
For years scientists have recognized a connection between plaque deposits on the brain and the progression of Alzheimer’s disease. Plaque deposits are formed when amyloid precursor protein (APP),
Under the agreement with the University of Massachusetts at Amherst (UMA), BioVeris acquired a first option for exclusive rights to commercialize products for possible use in the prevention,